Edition:
United States

Egalet Corp (EGLT.OQ)

EGLT.OQ on NASDAQ Stock Exchange Global Market

0.51USD
18 May 2018
Change (% chg)

$0.01 (+3.01%)
Prev Close
$0.50
Open
$0.50
Day's High
$0.52
Day's Low
$0.50
Volume
55,047
Avg. Vol
132,198
52-wk High
$3.47
52-wk Low
$0.48

Chart for

About

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using... (more)

Overall

Beta: 0.55
Market Cap(Mil.): $26.32
Shares Outstanding(Mil.): 52.88
Dividend: --
Yield (%): --

Financials

  EGLT.OQ Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -1.73 -- --
ROI: -63.66 -8.07 12.63
ROE: -- -10.87 14.50

BRIEF-Egalet Reports Q1 Loss Per Share $0.26

* EGALET CORP - NET PRODUCT SALES OF $6.3 MLN FOR QUARTER ENDED MARCH 31, 2018 COMPARED TO $5.4 MLN Source text for Eikon: Further company coverage:

May 08 2018

BRIEF-Egalet Corp Says A National Pharmacy Benefit Manager Has Placed Sprix Nasal Spray In A Tier 2 Preferred Position

* EGALET CORP - A NATIONAL PHARMACY BENEFIT MANAGER HAS PLACED SPRIX NASAL SPRAY IN A TIER 2 PREFERRED POSITION EFFECTIVE IMMEDIATELY

May 07 2018

BRIEF-Egalet Announces Two Large Regional Health Plans Placed Arymo® Er In Preferred Formulary Position

* EGALET ANNOUNCES TWO LARGE NORTHEAST REGIONAL HEALTH PLANS PLACED ARYMO® ER IN PREFERRED FORMULARY POSITION

Apr 17 2018

BRIEF-Egalet Says Filed Patent Infringement Lawsuit Against Teva Pharmaceuticals USA

* EGALET SAYS ON APRIL 4 UNITS OF CO FILED A PATENT INFRINGEMENT LAWSUIT IN U.S. DISTRICT COURT AGAINST TEVA PHARMACEUTICALS USA, INC - SEC FILING

Apr 05 2018

BRIEF-Egalet Reports Q4 Earnings Per Share $0.03

* EGALET REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 12 2018

BRIEF-Egalet Announces A Large Regional Health Plan

* EGALET ANNOUNCES A LARGE REGIONAL HEALTH PLAN PLACED ARYMO® ER AND SPRIX® NASAL SPRAY IN PREFERRED FORMULARY POSITIONS

Feb 28 2018

BRIEF-Egalet Says Received Notice From Teva Pharmaceuticals USA Of ANDA Submission For Approval To Market Generic Version Of Arymo ER Extended-Release Tablets

* EGALET - CO, UNIT RECEIVED NOTICE FROM TEVA PHARMACEUTICALS USA OF ANDA SUBMISSION FOR APPROVAL TO MARKET GENERIC VERSION OF ARYMO ER EXTENDED-RELEASE TABLETS

Feb 23 2018

BRIEF-Broadfin Capital Reports 9.99 Pct Passive Stake In Egalet Corp

* BROADFIN CAPITAL LLC REPORTS A 9.99 PCT PASSIVE STAKE IN EGALET CORP AS OF DEC 27, 2017 - SEC FILING Source text: (http://bit.ly/2lRMZcH) Further company coverage:

Jan 03 2018

BRIEF-Egalet Partners With Orapharma To Co-Promote Sprix Nasal Spray

* EGALET PARTNERS WITH ORAPHARMA TO CO-PROMOTE SPRIX® NASAL SPRAY

Jan 03 2018

BRIEF-Egalet Reduces Announces Refinancing Of Existing Convertible Notes

* EGALET REDUCES DEBT OBLIGATION, EXTENDS MATURITY AND LOWERS ANNUAL INTEREST PAYMENTS THROUGH REFINANCING OF EXISTING CONVERTIBLE NOTES

Dec 20 2017

Earnings vs. Estimates